Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
COVID-19 put many businesses on hold, but not biotech. This sector is growing at record speeds, and only a small portion of the capital deals are related to the pandemic.
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo Company for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) for multiple cancer types.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
Connolly, who has more than 20 years of experience in immunotherapy, will design the Institute’s overall research strategy and forge new partnerships between the institute and the industry.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
A new membrane filtration method could solve the problem of the excessive bioprocessing wastes that many say is a prime impediment to manufacturing pharmaceuticals in the United States.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
“Hopefully the approval process will go very quickly, and we think we have a winner here,” Trump told White House reporters on Wednesday.
According to the report, the options are worth $101 million and do not hinge on the clinical success of the vaccine program.
San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of its lead breast cancer treatment, as well as expand its ongoing research and development programs.